Research programme: RNA interference-based therapeutics - Generex/RXi

Drug Profile

Research programme: RNA interference-based therapeutics - Generex/RXi

Latest Information Update: 05 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Generex Biotechnology Corporation; RXi Pharmaceuticals Corporation
  • Developer Generex Biotechnology Corporation; RXi Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Gene silencing; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haematological malignancies

Most Recent Events

  • 02 May 2016 RXi Pharmaceuticals has patent protection for sd-rxRNA® platform in Europe
  • 30 May 2014 No development reported for Haematological malignancies in USA (Parenteral)
  • 06 Jan 2011 Early research in Haematological malignancies in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top